Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter G Rose

Showing results (51-60 of 201) with videos related to

Pageof 21
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 16, 2015
Impact of Age on 30-Day Mortality and Morbidity in Patients Undergoing Surgery for Ovarian CancerHaider Mahdi, Andrew Wiechert, David Lockhart, et al.
Journal of Gynecologic Oncology|May 26, 2017
Universal tolerance of nab-paclitaxel for gynecologic malignancies in patients with prior taxane hypersensitivity reactionsKathryn Maurer, Chad Michener, Haider Mahdi, et al.
Anti-Cancer Drugs|May 2, 2026
Response of undifferentiated and dedifferentiated endometrial cancer to pembrolizumab: a case reportPeter G Rose, Johanna Kelley, Aaron Petty, et al.
Gynecologic Oncology|June 7, 2014
Racial disparity in the 30-day morbidity and mortality after surgery for endometrial cancerHaider Mahdi, David Lockhart, Mehdi Moslemi-Kebria, et al.
Gynecologic Oncology|February 16, 2006
Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology GroupPeter G Rose, John A Blessing, Shashikant Lele, et al.
Gynecologic Oncology|February 6, 2007
Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma? Analysis of two Gynecologic Oncology Group (GOG) trialsBradley J Monk, Chunqiao Tian, Peter G Rose, et al.
Gynecologic Oncology|November 22, 2020
Impact of treatment modality on overall survival in women with advanced endometrial cancer: A National Cancer Database analysisLaura M Chambers, Xuefei Jia, Peter G Rose, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 2, 2015
The Impact of Percent Reduction in CA-125 Levels on Prediction of the Extent of Interval Cytoreduction and Outcome in Patients With Advanced-Stage Cancer of Müllerian Origin Treated With Neoadjuvant ChemotherapyHaider Mahdi, Kathryn A Maurer, Benjamin Nutter, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 11, 2017
Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial CarcinomaPeter G Rose, Shamshad Ali, Mehdi Moslemi-Kebria, et al.
Gynecologic Oncology|February 24, 2007
Yolk sac tumor of the ovary associated with endometrioid carcinoma with metastasis to the vagina: a case reportWilliam C McBee, Jennifer Brainard, Joram Sawady, et al.
Pageof 21

Showing results (51-60 of 201) with videos related to

Sort By:
Pageof 21
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 16, 2015
Impact of Age on 30-Day Mortality and Morbidity in Patients Undergoing Surgery for Ovarian CancerHaider Mahdi, Andrew Wiechert, David Lockhart, et al.
Journal of Gynecologic Oncology|May 26, 2017
Universal tolerance of nab-paclitaxel for gynecologic malignancies in patients with prior taxane hypersensitivity reactionsKathryn Maurer, Chad Michener, Haider Mahdi, et al.
Anti-Cancer Drugs|May 2, 2026
Response of undifferentiated and dedifferentiated endometrial cancer to pembrolizumab: a case reportPeter G Rose, Johanna Kelley, Aaron Petty, et al.
Gynecologic Oncology|June 7, 2014
Racial disparity in the 30-day morbidity and mortality after surgery for endometrial cancerHaider Mahdi, David Lockhart, Mehdi Moslemi-Kebria, et al.
Gynecologic Oncology|February 16, 2006
Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology GroupPeter G Rose, John A Blessing, Shashikant Lele, et al.
Gynecologic Oncology|February 6, 2007
Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma? Analysis of two Gynecologic Oncology Group (GOG) trialsBradley J Monk, Chunqiao Tian, Peter G Rose, et al.
Gynecologic Oncology|November 22, 2020
Impact of treatment modality on overall survival in women with advanced endometrial cancer: A National Cancer Database analysisLaura M Chambers, Xuefei Jia, Peter G Rose, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 2, 2015
The Impact of Percent Reduction in CA-125 Levels on Prediction of the Extent of Interval Cytoreduction and Outcome in Patients With Advanced-Stage Cancer of Müllerian Origin Treated With Neoadjuvant ChemotherapyHaider Mahdi, Kathryn A Maurer, Benjamin Nutter, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 11, 2017
Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial CarcinomaPeter G Rose, Shamshad Ali, Mehdi Moslemi-Kebria, et al.
Gynecologic Oncology|February 24, 2007
Yolk sac tumor of the ovary associated with endometrioid carcinoma with metastasis to the vagina: a case reportWilliam C McBee, Jennifer Brainard, Joram Sawady, et al.
Pageof 21